Results 121 to 130 of about 7,354 (172)

Ivacaftor affects the susceptibility of standard-of-care drugs used to treat <i>Mycobacterium abscessus</i> lung disease. [PDF]

Antimicrob Agents Chemother
Shrivastava A, Singh S, Boorgula GD, Galvez R-A, Srivastava S.   +4 more
europepmc   +1 more source

Development and Validation of a New LC-MS/MS Method for Simultaneous Quantification of Ivacaftor, Tezacaftor and Elexacaftor Plasma Levels in Pediatric Cystic Fibrosis Patients. [PDF]

Pharmaceuticals (Basel)
Mancini A, Simeoli R, Cristiani L, Cairoli S, Ciciriello F, Boni A, Alghisi F, Rossi C, Antonetti G, Vici CD, Fiocchi AG, Cutrera R, Goffredo BM.   +12 more
europepmc   +1 more source

Dried Blood Spot Method Development and Clinical Validation for the Analysis of Elexacaftor, Elexacaftor-M23, Tezacaftor, Tezacaftor-M1, Ivacaftor, Ivacaftor Carboxylate, and Hydroxymethyl Ivacaftor Using LC-MS/MS

Steffie E. M. Vonk, Marloes van der Meer‐Vos, Renate Kos, Anne H. Neerincx, Suzanne W. J. Terheggen‐Lagro, Josje Altenburg, Anke H. Maitland‐van der Zee, Ron A. A. Mathôt, E. Marleen Kemper   +8 more
openalex   +1 more source

Corrigendum: Effect of elexacaftor-tezacaftor-ivacaftor on nasal potential difference and lung function in Phe508del rats [PDF]

Nicole Reyne, Patricia Cmielewski, Alexandra McCarron, Ronan Smith, Elena K. Schneider‐Futschik, Nina Eikelis, Piraveen Pirakalathanan, David Parsons, Martin Donnelley   +8 more
openalex   +1 more source

Treatment with CFTR Modulators for Cystic Fibrosis: What a Pediatric Gastroenterologist Needs to Know. [PDF]

Children (Basel)
Jimenez DG, García Romero R, Martínez AR, Vicente Santamaria S.   +3 more
europepmc   +1 more source

Evaluation of Methicillin-Resistant <i>Staphylococcus aureus</i> Eradication in People With Cystic Fibrosis. [PDF]

J Pediatr Pharmacol Ther
Byerley EM, Yildiz VO, Sheikh SI, Novak KJ.   +3 more
europepmc   +1 more source

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase-1 in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Sankararaman S, Prunty L, Pamer C, Thavamani A, Roesch E, Schindler T.   +5 more
europepmc   +1 more source

Unmasking the true value of cystic fibrosis transmembrane conductance regulator modulators. [PDF]

ERJ Open Res
Azam A, Jones AM, Barry PJ.
europepmc   +1 more source

Simulation and Machine Learning Assessment of P-Glycoprotein Pharmacology in the Blood-Brain Barrier: Inhibition and Substrate Transport. [PDF]

Int J Mol Sci
Jorgensen C, Oliphant E, Barker M, López Martínez E, Thulasi S, Prior H, Franey BW, Gregory C, Oluwasegun J, Ajay A, Draheim RR.   +10 more
europepmc   +1 more source

Personalized tobramycin dosing in children with cystic fibrosis: an AUC₂₄-guided approach. [PDF]

Antimicrob Agents Chemother
Harwood KH, Duffull S, Shanthikumar S, Lei A, Ranganathan S, Robinson P, Sandaradura I, Lai T, Gwee A.   +8 more
europepmc   +1 more source